Additional Information
Market: ASX
Sector: Pharmaceuticals & Biotechnology
EPIC: STI
Latest Price: A$0.00  (0,00%)
52-week High: A$0.00
52-week Low: A$0.00
Market Cap: A$4.45M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Stirling Products
www.stirlingproducts.net

Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties.  Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.

The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.

Stirling operates through three main business units each managed by proven industry specialist managers:

- Pharmaceutical & Healthcare
- Research & Development
- Animal Products

Pdf

Stirling Products appoints former ResMed director for drug inhalation device unit

13th May 2010, 9:49 am

Pharmaceutical and healthcare company, Stirling Products (ASX:STI) has appointed former ResMed Limited and Ventracor director, Ross Harricks to commercialise the drug inhalation device.

Harricks worked as marketing executive for the Nucleus Group, then Australia's leading international
medical technology group, Telectronics - pacemakers; Cochlear - bionic ear, Ausonics - ultrasound and Medtel - distribution.

Harricks has been involved at all levels of development and raised funds, guided the design of products, obtained regulatory approvals worldwide (FDA, CE Mark) and built widespread technology adoption and endorsement with leading medical institutions and opinion leaders in US and Europe.

Stirling Products' delivery devices are designed to provide for a dramatically improved safety profile of "blockbuster drugs" when many of these drugs move off patents to become generic products.

Drugs like the Pfizer drug Lipitor is moving off patent to generic next year.  Despite a decline, it had global sales of US$11.4 billion in 2009, providing a large opportunity for companies with a unique and differentiated drug delivery platform.

This creates an opportunity for Stirling Products to package the generic version with its drug delivery device to provide a new proprietary package that can be marketed at a significant premium to the other generic versions due to an expected improved safety profile in many cases.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.